The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
about
Q24186229Regulation of Hepatic Stellate Cells and Fibrogenesis by Fibroblast Growth FactorsReview article: bile acid diarrhoea - pathogenesis, diagnosis and managementEffects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea.Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome.Recent advances in the development of farnesoid X receptor agonistsSystematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?Therapeutic targeting of bile acidsReview article: biomarkers and personalised therapy in functional lower gastrointestinal disorders.Understanding the mechanisms of faecal microbiota transplantation.Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242.Secretory diarrhoea: mechanisms and emerging therapies.Randomized controlled trial of cholestyramine and hydrotalcite to eliminate bile for capsule endoscopyUnderlying molecular and cellular mechanisms in childhood irritable bowel syndromeNew and Investigational Agents for Irritable Bowel Syndrome.Obeticholic Acid: First Global Approval.Bile acid disease: the emerging epidemic.Incidence and predictive factors for positive 75SeHCAT test: improving the diagnosis of bile acid diarrhoea.Mechanisms of triglyceride metabolism in patients with bile acid diarrhea.A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolismModeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage.Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis.A Twist in the Tale of a Pig Model of Short-Bowel Syndrome.Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases.Chenodeoxycholic acid stimulated fibroblast growth factor 19 response - a potential biochemical test for bile acid diarrhoea.Existing and emerging therapies for managing constipation and diarrhea.Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.Dissecting Molecular Mechanisms in Bile Acid Diarrhea.Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19.Farnesoid X Receptor Expression in Microscopic Colitis: A Potential Role in Disease Etiopathogenesis.In Silico Analysis Identifies Intestinal Transit as a Key Determinant of Systemic Bile Acid Metabolism.Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASHBile acid signaling and bariatric surgery
P2860
Q24186229-FD91CA49-9522-4586-A626-EFFE5CAC94D6Q28076863-4F6476EA-7BBA-42DB-964E-9491DA71BA5AQ28273649-0C74C8D1-DA8B-4002-8911-24F8C9B1A1ADQ33632959-E07A6A16-DD7C-41EB-A809-B7633546EBCDQ33711736-C6A6F404-21E2-43C7-9DB0-32C99B9388B7Q34464043-74D033BC-0AEC-48D5-8D51-CAF63ABD622EQ35724871-2249DB00-2A0F-460B-88E1-3181FED07E2AQ35958534-465AAE18-329F-40AF-99CB-A810BA80635DQ36021269-57DA50E2-DC43-4DBE-A6AC-A543605BCB65Q36058419-32087462-3C67-48A4-92CC-80F3C2061D06Q36082843-CB696CF5-3BF6-4CBB-A8E5-58488E318DEEQ36191276-77FD6896-B1D9-48C3-A605-21932F7A3CA2Q36673563-D1398BD2-E156-4350-A642-33CAD322824FQ36755441-5A3946FC-5EDC-4179-81C8-7F870A49B0E6Q38515695-B4C64F18-6858-42EC-906A-4FEEE9C7E909Q38601834-6F81AD76-0F23-4C33-BA63-F4937A2EA985Q38894300-447F9499-792F-4CF6-B5F2-E3FAE7605B63Q39124316-775D0AD2-6451-4546-9DFB-E1D94EE6C455Q39170275-AF266484-ACE6-4CA2-BF94-AE427C441F2DQ39444895-6A6660A6-1915-4A8A-967C-B585C761B784Q40858310-631E2439-D0E0-4B7C-B7EE-F7B311B198E3Q41785704-4BC95759-5D20-4DF9-AB85-60410369E4E4Q43270593-EE5924CD-12EE-4BE5-948C-A83146838475Q47095712-EA7E24BD-835C-4A23-B8F7-D2F417B191EAQ47441583-0E1D180A-A53A-4FB2-B2B5-F5748DE507A9Q48319424-9421A66F-ACDC-4FC1-98CE-5AB489365083Q49677641-37E1A4A3-EEA3-4FC8-ADC2-02653A6D47EAQ50535134-9FA7C398-6204-4A88-A3D4-A70BB08EDC50Q51286764-72B2B2B5-BC4C-4E3E-89F3-FF5B4DBFF776Q51310817-24F2C459-1925-4EE0-8278-6ECE30FE6B5EQ51750234-60B6007A-01F5-4FE9-9CF0-E81EB33A1F71Q55333816-F2E804DC-FDE1-4287-BCCA-BA34AED504EDQ55345479-EA4A7078-C753-460E-8508-AD472EE8297BQ57099106-0DABC0C4-2F99-4DCD-85A7-BAAFADB196A4Q57124605-C47B1302-C782-43C7-A844-245E2C834A62
P2860
The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The response of patients with ...... ptor agonist obeticholic acid.
@ast
The response of patients with ...... ptor agonist obeticholic acid.
@en
The response of patients with ...... ptor agonist obeticholic acid.
@nl
type
label
The response of patients with ...... ptor agonist obeticholic acid.
@ast
The response of patients with ...... ptor agonist obeticholic acid.
@en
The response of patients with ...... ptor agonist obeticholic acid.
@nl
prefLabel
The response of patients with ...... ptor agonist obeticholic acid.
@ast
The response of patients with ...... ptor agonist obeticholic acid.
@en
The response of patients with ...... ptor agonist obeticholic acid.
@nl
P2093
P2860
P921
P356
P1476
The response of patients with ...... eptor agonist obeticholic acid
@en
P2093
D A Shapiro
I M Johnston
M E Pruzanski
P2860
P356
10.1111/APT.12999
P407
P577
2014-10-20T00:00:00Z